Background: FOXE1, a thyroid-specific transcription factor also known as TTF-2, was recently identified as a major genetic risk factor for papillary thyroid carcinoma (PTC). Its role in thyroid carcinogenesis, however, remains unknown. The purpose of the present study was to assess the relationship between the FOXE1 immunohistochemical features and the clinical and genetic characteristics of PTC.
INTRODUCTION
Thyroid cancer is the most common endocrine malignancy displaying a worldwide trend in rising incidence during the last few decades. Recently, it was reported to be among the top 5 leading malignancies among women in USA (1) . In Japan, age-standardized rate of thyroid cancer increased from 1.4 in 1975 to 5.1 in 2007 (per 100,000 population) (2) .
Papillary thyroid carcinoma (PTC) is the major histological type which accounts for about 85% of all thyroid cancers (3) .
Extensive studies in PTC have identified key molecular events of thyroid carcinogenesis including BRAF or RAS family mutations and gene rearrangements (RET/PTC, TRK) which activate the MAP kinase pathway (4) . In addition to advances in understanding oncogenic changes, there has been substantial progress in the discovery of inherited genetic factors modulating risk for PTC. Several recent genetic association studies, using genome-wide (5, 6) or candidate gene approach (7) (8) (9) (10) , concordantly revealed single nucleotide polymorphisms (SNPs) in a proximal region around (rs965513: G>A) or immediately at (rs1867277: c.-238G>A) the forkhead box E1 (FOXE1) gene locus as genetic markers of susceptibility to PTC in ethnically diverse populations.
The intronless FOXE1 gene located on chromosome 9q22 encodes a DNA-binding protein also known as thyroid transcription factor 2 (TTF-2), a member of the forkhead/winged helix family of evolutionarily conserved transcription factors (11) . In humans, FOXE1 is a key player in thyroid organogenesis, thyrocytes precursor migration and differentiation with onset of expression in the thyroid primordium at Carnegie stage 15 (12, 13) . In adulthood FOXE1 is detectible in basal keratinocytes of the epidermis, hair follicles and in the exocrine cells of testicular seminiferous tubules (14) (15) (16) . Recessive inactivating mutations in FOXE1 are the cause of Bamforth-Lazarus syndrome characterized by congenital hypothyroidism due to thyroid agenesis, cleft palate, choanal atresia and spiky 8 hairs (14) . FOXE1 involvement in carcinogenesis has been demonstrated in basal and squamous cell carcinomas of the skin (16, 17) , breast cancer (18) , and pancreatic cancer (19) .
FOXE1 is a transcription activator of thyroperoxidase and thyroglobulin genes (20, 21) . In turn, FOXE1 expression is upregulated in cells cultured in the presence of TSH, insulin or IGF-1 which are essential for thyroid follicular cells homeostasis (22). Despite genetic studies strongly implicate FOXE1 in PTC and there is an alteration of FOXE1 expression and localization in cancer cells, its role in tumor development remains unknown. Therefore, in this study we analyzed the patterns of FOXE1 immunohistochemical expression in PTC and adjacent normal thyroid in details, and investigated their relationship with morphological characteristics of the tumor and patients' genotypes.
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MATERIALS AND METHODS
Patients and tissue samples
Initially, 127 cases of PTC were collected from the archive of the Department of Tumor and Diagnostic Pathology, Nagasaki University Graduate School of Biomedical Sciences. Hematoxylin-eosin slides were reviewed to confirm the presence of neoplastic and adjacent non-neoplastic thyroid tissues large enough to assess tumor/normal tissue interface and distant areas of both counterparts (at least 0.5 cm from the tumor border). Seventy-three cases did not match such criteria and were excluded from the study. Another 6 cases were excluded due to the lack of archived material for nucleic acid extraction.
Thus, a total of 48 PTC tissue samples operated on for thyroid cancer between 1977 and 2011 in Nagasaki University Hospital were investigated. Protocols of the study were approved by the Ethical Committee of Nagasaki University. Clinicopathological information was retrieved from pathology records. Tumor were staged according to UICC TNM classification of malignant tumors (26). Pathological diagnosis was based on the WHO standards (27) and was confirmed independently by two pathologists (A.B. and M.N.).
Microscopic features were categorized as follows: the presence of tumor capsule (absent, partial, full; 0-2), oxyphilic changes (none, focal, moderate, severe, pure oxyphilic tumor; 0-4), multifocality (yes or no; 1-0), intraglandular spread (yes or no; 1-0), extrathyroidal extension (yes or no; 1-0), vascular invasion (yes or no; 1-0), intratumoral lymphocytic infiltration (absent, focal, severe; 0-2), peritumoral lymphocytic infiltration (absent, focal, severe; 0-2), intratumoral fibrosis (absent, mild, moderate, extensive; 0-3).
Tumor growth patterns (papillary, follicular or solid) were scored and expressed as percentage of each component. Histologically evident concomitant thyroid diseases such as hyperplastic nodules, multinodular goiter, chronic lymphocytic thyroiditis, Hashimoto's thyroiditis and follicular adenoma were also recorded. Patient' profiles and tumor characteristics are summarized in Table 1 .
Immunohistochemical procedures
Immunohistochemistry was performed using goat anti-human FOXE1 (ab5080, polyclonal, Abcam, USA) and rabbit anti-human MCM2 (#3619, monoclonal, Cell Signaling, USA). MCM2 is a member of the pre-replication complex required for the initiation of DNA replication and is widely used as a surrogate immunohistochemical marker of proliferation (28, 29).
Four-micron thick paraffin-embedded tissue sections were deparaffinized in xylene and rehydrated through graded alcohols. Heat-induced epitope retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) using intermittent heating in four cycles of 5 min each in a 700 W microwave oven. Endogenous peroxidase activity was blocked by immersion in 3% The specificity of FOXE1 staining was validated by blocking the antibody with an excess of immunizing peptide (AYPGGIDRFVSAM; Hokkaido System Science, Sapporo, Japan). Sections were incubated with a mixture of anti-FOXE1 antibody and a gradual excess of blocking peptide overnight at 4°C followed by IHC staining as described. Negative controls (omitted primary antibody) were also stained simultaneously. A decrease in staining intensity was observed in a blocking peptide concentration-dependent manner ( Fig. S1 ). No staining was seen in negative controls.
Immunohistochemical scores
The evaluation of the FOXE1 score and MCM2 labeling index was performed by observers blinded to clinical, demographic and genetic data. The intensity of immunoreactivity was classified as negative (0), mild (1), intermediate (2) and strong (3).
The proportion score was semi-quantitative and comprised the percentage of stained tumor cells ranging from 0 to 100% in 5% increments (0%, 5%, 10%, etc.). The resultant score was calculated by multiplying staining intensity by the proportion score.
FOXE1 scores were calculated separately for nuclear and cytoplasmic compartments.
Based on the preliminary observations, four distinct zones in each section were distinguished.
These were the tumor (T) and normal (N) counterparts both subdivided into the "close" and "distant" areas with regard to the proximity to the border between cancer tissue and adjacent normal thyroid tissue. The "T close" and "N close" were defined as areas of parenchyma extending up to 300 µm from the tumor border for both cancerous and non-neoplastic thyroid. Correspondingly, the "T distant" and "N distant" were the areas outside (> 300 µm) the "close" ones. FOXE1 score was evaluated at ×400 magnification throughout each zone in cell nuclei and cytoplasm separately. The total FOXE1 score is reported as the sum of nuclear and cytoplasmic scores in cancer or normal tissues across all the zones. At least 1000 cells were counted in 4 random fields of each zone.
MCM2 index was calculated as a percentage of positive cells (nuclear staining regardless of intensity) among at least 1000 tumor cells counted in 4 random fields in the "T close" and "T distant" zones. Non-epithelial cells (e.g., lymphocytes) were ignored.
SNP genotyping
Tissues were manually microdissected from three 4 µm formalin-fixed paraffin embedded sections and DNA was extracted using RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. DNA quantification was performed using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, USA). SNPs (rs965513 and rs1867277) were detected by direct sequencing. Primers were designed with Primer Express Software Version 1.0 (Applied Biosystems, USA) to yield relatively short PCR products (around 100 bp) suitable for sequencing with the forward primer. Primer sequences were as follows: 5'- 
Statistical analysis
FOXE1 is a transcription factor whose principal functions are expected to be in the nucleus. Thus, all cases in the study were dichotomized according to the nuclear immunohistochemical FOXE1 scores in either the "T close" or "N close" zones into (i) cases with scores below or (ii) equal to or greater than median. The subgroups thus defined were compared for baseline factors, clinical and tumor-related characteristics by Fisher's exact test or its extension (http://in-silico.net/tools/statistics/fisher_exact_test) for categorical data and 
RESULTS
Immunohistochemical FOXE1 staining
Normal thyroid follicular cells exhibited nuclear and cytoplasmic FOXE1 staining.
Nuclear immunoreactivity was strong or moderate with solid appearance while the cytoplasm displayed a focal granular staining of weak intensity. Approximately one-third of all nuclei were FOXE1-negative whereas no cytoplasmic expression was noticed in about 25% of cells ( Fig. S2a) . A more uniform pattern of FOXE1 expression was observed in cells in the vicinity of the tumor border confined within ≤ 300 μm tissue layer ( Fig. 1a-b ). In all cases most cells showed strong nuclear and moderate cytoplasmic (predominantly along the luminal membrane) immunoreactivity (Fig. S2b ).
In tumors, FOXE1 expression was moderate-to-strong, thus the neoplastic area was easily distinguishable from adjacent normal parenchyma on low-power microscopy (Fig. 1b) .
Cytoplasmic immunoreactivity was observed in all cancer cells regardless of their spatial localization. Nuclear expression often had rim-like appearance reflecting chromatin distribution in PTC nuclei ( Fig. 1e ). Similarly to the normal thyroid, FOXE1 expression in the cells at or in close proximity to the tumor border showed the highest intensity of cytoplasmic and nuclear expression ( Fig. S2c ). Neoplastic cells in the tumor center exhibited markedly lower intensity often accompanied by the loss of nuclear expression ( Fig. S2d ).
Cancer cells embedded in fibrous tissue displayed increased immunoreactivity while, in contrast, FOXE1 expression in the areas with oxyphilic changes was low.
FOXE1 expression patterns in PTC
The total FOXE1 score (combining close and distant zones) was significantly higher in cancer tissue as compared to normal thyroid (p < 0.001) (Fig. 2) . This was mostly due to the higher cytoplasmic FOXE1 expression in cancer cells (p < 0.001). In contrast, nuclear expression was higher in non-neoplastic thyroid than in tumor although with borderline significance (p = 0.048). Cytoplasmic FOXE1 expression was an essential feature of cancer cells while prominent nuclear expression was characteristic for normal cells. Of note, all cancer cells but not all normal cells were immunopositive for FOXE1.
Statistical analysis confirmed our preliminary observations of a gradient in FOXE1
expression between central and peripheral areas of tumor and normal tissues ( Fig. S2a-d (Fig. 1c, Fig. S2a ).
2) In the "N close" zone (normal thyroid tissue immediately adjacent to invasive or encapsulated tumor border, i.e. ≤ 300 μm) most cells were FOXE1-positive showing the highest nuclear and moderate cytoplasmic intensity (Fig. 1d, Fig. S2b ).
3) In the "T close" zone (invasive tumor front or subcapsular region within 300 μm, regardless tumor border contacts adjacent thyroid parenchyma or extrathyroidal tissues) virtually all cells demonstrated the strongest cytoplasmic and moderate nuclear FOXE1 expression ( Fig. 1e, Fig. S2c) . The presence or absence of a capsule as well as its thickness did not affect the size of the zone.
4)
The "T distant" zone (bulk PTC tissue at a distance > 300 μm from the border) shows mainly monomorphic low to moderate cytoplasmic expression with negative or weak nuclear staining (Fig. 1f, Fig. S2d ).
The cytoplasmic and nuclear FOXE1 scores in both tumor and normal tissue moderately, but significantly, correlated with each other in all four zones (p < 0.002 for any relationship, R 2 range 0.19-0.52). However, there was no correlation between any FOXE1 scores in each zone when normal and cancer tissues were compared pairwise (p > 0.07 for any relationship).
Of note, in our study papillary microcarcinomas showed the same pattern as largesized tumors (p > 0.34 for difference in any FOXE1 score). Also no significant variations in FOXE1 expression patterns were found between histological variants of PTC (p > 0.27 for difference in any FOXE1 score).
MCM2 expression by immunohistochemistry
To address whether FOXE1 distribution patterns could be associated with proliferation, MCM2 staining was employed. A diffuse nuclear immunostaining was observed across neoplastic tissue (Fig. 1g ). There was marked inter-tumor variation of labeling index ranging from 0.96 to 54.58 (24.88, mean). In most PTCs MCM2 expression was higher in the invasive zone than in the central area ( Fig. 1j-k) , 29.6±14.4 vs. 20.16±12.5 (p = 0.003). However, tumors measuring ≤ 1 cm (i.e., microcarcinomas) failed to display this pattern, 29.4±14.6 vs. 24.3±14.3 (p = 0.672). Cancer epithelial cells in the areas of lymphocytic infiltration were often strongly positive for MCM2. Furthermore, PTCs with severe intratumoral lymphocytic infiltration showed a significantly higher MCM2 index (p = 0.021). In addition, PTCs displaying oxyphilic changes demonstrated elevated labeling index, 35.7±12.2 vs. 25.2±14.5 (p = 0.016). MCM2 index correlated with total and nuclear FOXE1 scores in both close and distant neoplastic zones (p < 0.05 for any comparison) but not with cytoplasmic FOXE1 score (p > 0.17 for any comparison).
In the normal thyroid MCM2 expression was exceedingly low. While normal follicular epithelium immediately adjacent to the tumor showed slightly higher MCM2 score than that at the greater distance, the number of positive cells accounted for less than 1% ( Fig.   1h -i). MCM2 labeling indices in the normal thyroid did not correlate with any of the corresponding FOXE1 scores.
Based on the difference in FOXE1-MCM2 correlations between normal thyroid and
cancer tissue we concluded that FOXE1 expression does not specifically associate with cell proliferation.
Genetic analysis of FOXE1 polymorphism
Two SNPs in the FOXE1 locus have been reported to significantly associate with thyroid cancer risk. The strongest marker, rs965513 (G>A) (5, 6, 8, 9) , lies about 57 kb upstream (centromeric) to FOXE1 and a functional rs1867277 (G>A) is located within the FOXE1 5'UTR (c.-238) (7) . The two SNPs were successfully genotyped in 47 and 46 cases, respectively. In agreement with our previous independent study (8) and dbSNP build 137 (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp), rs965513 had minor allele frequency of 0.053 (0.057 in the Japanese population in both references) and rs1867277 that of 0.170 (0.172 and 0.108 according to the two references, respectively). There was no strong evidence for linkage disequilibrium between the two SNPs in the present series (D' = 0.21) in line with our earlier claim (D' = 0.23) (8) .
Association of immunohistochemical FOXE1 expression with clinicopathological and genetic parameters
Nuclear FOXE1 expression in the "T close" and "N close" zones were chosen as the outcome variables. Table 2 , on univariate analysis of the "T close" zone none of the parameters was significant except MCM2 immunohistochemical expression in the distant zone of the tumor as mentioned above. Nuclear FOXE1 expression in the "N close" zone associated with only two parameters, the intratumoral lymphocytic infiltration and MCM2 immunohistochemical expression in the distant zone of the tumor.
As shown in
The results of multivariate logistic regression analysis demonstrated that among all variables tested only two, the multifocality (p = 0.032) and rs1867277 polymorphism in the FOXE1 5' UTR (p = 0.037), significantly associated with nuclear FOXE1 expression in the "T close" zone; capsular invasion displayed marginal significance (p = 0.051) as shown in Table 3 . Both multifocality and variant genotype other than homozygous for the major allele (the dominant model of inheritance) associated with the higher FOXE1 expression. In contrast, the regression models for the "N close" zone performed poorly and no variables significantly associating with nuclear FOXE1 expression in this zone could be identified.
DISCUSSION
Our study reports, for the first time, Tumor-associated macrophages are also localized predominantly in the peripheral areas of follicular variant of PTC (39) . Our observation of the difference in FOXE1 expression between PTC periphery and tumor center is generally in line with the increased cellular activity at the tumor border.
However, a similar gradient was also detected in non-neoplastic thyroid tissue adjacent to PTC. This form of distribution has not been sufficiently described for the normal counterpart. Tumor cells can directly influence surrounding host tissue but this is mostly known to affect peritumoral stroma which undergoes changes resembling some properties of cancerous stroma (40) . It is unlikely that physical contact between cancer and normal cells at the tumor border is the reason for local FOXE1 overexpression since there was no principal difference in expression patterns between encapsulated and non-encapsulated tumors.
Moreover, there was no relationship to capsule thickness or tumor size. A possibility exists that FOXE1 overexpression may be due to humoral factors secreted by cancer or normal cells, either epithelial or stromal, but this hypothesis requires further investigation. The fact that nuclear FOXE1 expression in normal thyroid tissue in vicinity of the tumor border did not associate on multivariate analysis with any tumor characteristic hampers assumptions about the significance of such accumulation. It could be a reactive change but whether it provides a positive or negative feedback to the tumor remains to be established.
In order to explain FOXE1 overexpression around the tumor border, we explored 20 several markers. We observed that MCM2 index decreased with increasing distance from the tumor border in the cancer tissue. This statistically correlated with FOXE1 scores. However, a similar pattern and correlation were not observed in the normal tissue pointing at the lack of a direct link of FOXE1 overexpression to cell proliferation per se. To address stromal effects, we assessed the distribution of tumor-associated macrophages which are known to be important regulators of cancer microenvironment (41) . CD68 immunostaining demonstrated preferential accumulation of macrophages around the tumor border either on the tumor or normal tissue side but large inter-specimen variations were observed; CD68 staining did not correlate with any FOXE1 scores in either tumor or normal tissue (A.B., unpublished data).
The effect of reactive oxygen species was examined using an antibody to 4-HNE, a marker of peroxide-induced damage (42) . Immunostaining showed antigen localization in the cytoplasm of normal thyroid cells while cancer tissue was predominantly negative, probably due to the downregulation of thyroid peroxidase in PTC; also, no gradient staining was observed (A.B., unpublished data). Thus, neither of these biological processes could explain the "four zone" Intracellular localization of FOXE1 appeared to be markedly different in cancer and normal epithelium. In our series, nuclear FOXE1 staining was intense to moderate with weak cytoplasmic signal in the normal thyroid which is in agreement with an earlier report (15) .
PTC tissues exhibited an evident cytoplasmic overexpression and decreased accumulation in the nucleus. Loss of nuclear FOXE1 expression in thyroid tumors has been proposed to associate with tumor dedifferentiation, the strongest to be in anaplastic thyroid carcinoma which is virtually devoid of FOXE1 (24, 25) .
The aberrant cytoplasmic FOXE1 expression in PTC cells may be suggestive of its relationship to cancer biology. For example, a forkhead-box domain-containing transcription factor FOXP1 shows loss of nuclear expression with more frequent cytoplasmic accumulation in endometrial carcinoma compared with normal endometrium (43) . The aberrant cytoplasmic localization of β-catenin has prognostic significance in thyroid papillary microcarcinoma and other cancers (44, 45) . However, we do not propose that FOXE1 might be used for PTC prognostication as all tumors in our series, regardless of their size or stage, displayed protein translocation to the cytoplasm. The mechanism of FOXE1 accumulation in the cytoplasm has not been studied so far. It is tempting to speculate that one or several signaling cascades might result in FOXE1 modification causing its stabilization and export to or retention in the cytoplasm. For example, this may be due in part to the Shh/Gli and Wnt pathways both of which regulate FOXE1 expression (16, (46) (47) (48) and are active in PTC (49, 50) . The MAP kinase cascade, whose functioning in PTC due to one or another oncogene is expected, would unlikely be a candidate since phospho-ERK1/2 expression on immunohistochemistry has been reported to be irregular and did not follow ordered spatial distribution (51) (52) (53) (54) (55) . Further functional studies are necessary to clarify whether FOXE1 translocation to the cytoplasm is an active contributor to PTC or a consequence of cell transformation.
We also made an attempt to link FOXE1 expression with the results of genetic association studies which pointed to FOXE1 as the genetic determinant of thyroid cancer.
Two SNPs, the rs965513 located upstream of FOXE1 and rs1867277 in the 5'UTR of the gene are strongly associated with the risk of PTC. It is worth noting that rs965513 is the strongest genetic marker of thyroid cancer (principally of PTC) in both (adult) sporadic (5, 8, 9) and (mostly childhood and adolescent) radiation-induced PTC (6) . Activated oncogenes underlying PTC in adult and young patients are generally distinct being the point mutations (BRAF, RAS family) or gene rearrangements (RET/PTC, TRK), respectively (4). Therefore, the role of FOXE1 in thyroid carcinogenesis would be rather more universal and independent of the type of oncogenic drive.
According to our analysis, the presence of risk allele (A) in rs1867277 was associated with higher nuclear expression of FOXE1 in cancer cells at the tumor border. It has been demonstrated that rs1867277 (A) is responsible for increased FOXE1 expression through the recruitment of the USF1/USF2 transcription factors (7) . Although there have been no studies specifically focusing on USF1 and/or USF2 expression in PTC, data from microarray database suggest that the mRNA levels of these transcription factors are not decreased in cancer tissue as compared to the normal thyroid (https://www.oncomine.org/resource/main.html#v:15). USF1 and USF2 transcripts are also recoverable from normal rat thyroid cell line FRTL-5 (56) . Taking these reports together with our results, one may suggest that transcriptional regulation of the FOXE1 gene by USF1/USF2 may be functional in PTC.
Interestingly, rs1867277 in Caucasian individuals was recently reported to be in strong linkage disequilibrium with the FOXE1 region encoding polyalanine stretch (10) . Risk allele (rs1867277, A) corresponds to the 16 alanine repeats-bearing FOXE1 whose transcriptional activity is modestly different from that of the major 14 alanine isoform. It has also been claimed that FOXE1 mRNA was expressed more abundantly in thyroid biopsies from PTC patients homozygous for 16 alanine allele than in patients with homozygous 14 alanine genotype (57) . While there are no data on the relationship between the number of alanine repeats and protein stability, the higher FOXE1 mRNA expression level, presumably due to both USF1/USF2 recruitment and the higher conformational stability, might result in 
